The Charles R. Bronfman Institute for Personalized Medicine (IPM) explores how genetic information and environmental exposure affect each person's risk to develop certain diseases and response to medication.

The Institute examines how this new model of genome-informed personalized healthcare may be translated in clinical settings to advance the practice, delivery and economics of health care.

While personalized medicine is transforming the health system as we know it, we are bridging the gap between genomics research and patient care.  Read More

Meet the Director

Erwin P. Bottinger, MD, is Director of the Charles R. Bronfman Institute for Personalized Medicine and Professor of Medicine, Nephrology, and of Pharmacology and Systems Therapeutics.  Read More

NEWS

Mount Sinai Receives $3.4 Million Grant to Initiate First-Of-Its-Kind Study of Personalized Medicine in the Clinical Setting 
August 18, 2011 - Dr. Erwin Bottinger and his team are initiating the largest study to date using genetic information to help tailor individualized treatments in heart disease patients.

 

Data From Mount Sinai Biobank Provides Critical Insight Into Personalized Medicine  
May 4, 2011 - Mount Sinai researchers find that population labels may not be helpful in predicting disease risk or guiding how a patient will respond to certain medications, as previously thought.

 

Mount Sinai Charles R. Bronfman Institute for Personalized Medicine Biobank Enrolls 14,000 
February 5, 2011 - The Mount Sinai IPM Biobank, a unique institution that serves Mount Sinai’s many genomic research projects, has enrolled 14,000 Mount Sinai patients.

 
VIEW ALL
Useful Links
Conduits Genomics Institute